Federal Advisory Committee; Meeting of the Uniform Formulary Beneficiary Advisory Panel, 30003 [2010-12867]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 103 / Friday, May 28, 2010 / Notices
DEPARTMENT OF DEFENSE
Office of the Secretary
Federal Advisory Committee; Meeting
of the Uniform Formulary Beneficiary
Advisory Panel
AGENCY: Assistant Secretary of Defense
(Health Affairs), DoD.
ACTION: Notice of meeting.
SUMMARY: Under the provisions of the
Federal Advisory Committee Act of
1972 (title 5, United States Code
(U.S.C.), Appendix, as amended) and
the Government in the Sunshine Act of
1976 (5 U.S.C. 552b, as amended) the
Department of Defense announces that
the Uniform Formulary Beneficiary
Advisory Panel (hereafter referred to as
the Panel) will meet on June 24, 2010,
in Washington, DC. The meeting is open
to the public from 9 a.m. to 12 p.m., but
seating is limited. A closed
Administrative Work Meeting will be
held from 8 a.m. to 9 a.m.
DATES: The open meeting will be held
on June 24, 2010, from 9 a.m.–12 p.m.
Prior to the open meeting the Panel will
conduct an Administrative Work
Meeting from 8 a.m. to 9 a.m. that is
closed to the public.
ADDRESSES: The meeting will be held at
the Naval Heritage Center Theater, 701
Pennsylvania Avenue NW., Washington,
DC 20004.
FOR FURTHER INFORMATION CONTACT:
Lieutenant Colonel Stacia Spridgen,
Designated Federal Officer, Uniform
Formulary Beneficiary Advisory Panel,
2450 Stanley Road, Suite 208, Ft. Sam
Houston, TX 78234–6102, Telephone:
(210) 295–1271, Fax: (210) 295–2789, Email: Baprequests@tma.osd.mil.
SUPPLEMENTARY INFORMATION:
Purpose of Meeting
The Panel will review and comment
on recommendations made to the
Director, TRICARE Management
Activity, by the Pharmacy and
Therapeutics Committee regarding the
Uniform Formulary.
jlentini on DSKJ8SOYB1PROD with NOTICES
Meeting Agenda
Sign-In; Welcome and Opening
Remarks; Public Citizen Comments;
Scheduled Therapeutic Class Reviews—
Alpha Blockers for Benign Prostatic
Hyperplasia, Antilipidemics I,
Designated Newly Approved Drugs and
Drugs recommended for non-formulary
placement due to non-compliance with
Fiscal Year 2008 National Defense
Authorization Act, Section 703; Panel
Discussions and Vote; and comments
following each therapeutic class review.
VerDate Mar<15>2010
17:43 May 27, 2010
Jkt 220001
Meeting Accessibility
Pursuant to 5 U.S.C. 552b, as
amended, and 41 CFR 102–3.140
through 102–3.165, and the availability
of space this meeting is open to the
public. Seating is limited and will be
provided only to the first 220 people
signing in. All persons must sign in
legibly.
Administrative Work Meeting
Prior to the public meeting the Panel
will conduct an Administrative Work
Meeting from 8 a.m. to 9 a.m. to discuss
administrative matters of the Panel. The
Administrative Work Meeting will be
held at the Naval Heritage Center (see
ADDRESSES). Pursuant to 41 CFR 102–
3.160, the Administrative Work Meeting
will be closed to the public.
Written Statements
Pursuant to 41 CFR 102–3.105(j) and
102–3.140, the public or interested
organizations may submit written
statements to the membership of the
Panel at any time or in response to the
stated agenda of a planned meeting.
Written statements should be submitted
to the Panel’s Designated Federal Officer
(see FOR FURTHER INFORMATION CONTACT).
The Designated Federal Officer’s contact
information can be obtained from the
General Services Administration’s
Federal Advisory Committee Act
Database—https://www.fido.gov/
facadatabase/public.asp.
Written statements that do not pertain
to the scheduled meeting of the Panel
may be submitted at any time. However,
if individual comments pertain to a
specific topic being discussed at a
planned meeting, then these statements
must be submitted no later than 5
business days prior to the meeting in
question. The Designated Federal
Officer will review all submitted written
statements and provide copies to all the
committee members.
Public Comments
In addition to written statements, the
Panel will set aside 1 hour for
individuals or interested groups to
address the Panel. To ensure
consideration of their comments,
individuals and interested groups
should submit written statements as
outlined in this notice; but if they still
want to address the Panel, then they
will be afforded the opportunity to
register to address the Panel. The
Panel’s Designated Federal Officer will
have a ‘‘Sign-Up Roster’’ available at the
Panel meeting, for registration on a firstcome, first-serve basis. Those wishing to
address the Panel will be given no more
than 5 minutes to present their
comments, and at the end of the 1-hour
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
30003
time period no further public comments
will be accepted. Anyone who signs up
to address the Panel, but is unable to do
so due to the time limitation, may
submit their comments in writing;
however, they must understand that
their written comments may not be
reviewed prior to the Panel’s
deliberation. Accordingly, the Panel
recommends that individuals and
interested groups consider submitting
written statements instead of addressing
the Panel.
Dated: May 25, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison
Officer, Department of Defense.
[FR Doc. 2010–12867 Filed 5–27–10; 8:45 am]
BILLING CODE 5001–06–P
DEPARTMENT OF DEFENSE
Office of the Secretary
[Docket ID: DOD–2010–OS–0069]
Privacy Act of 1974; System of
Records
AGENCY:
Defense Intelligence Agency,
DoD.
ACTION: Notice to delete a system of
records.
SUMMARY: The Defense Intelligence
Agency proposes to delete a system of
records notice in its existing inventory
of records systems subject to the Privacy
Act of 1974, (5 U.S.C. 552a), as
amended.
DATES: This proposed action will be
effective without further notice on June
28, 2010 unless comments are received
which result in a contrary
determination.
ADDRESSES: You may submit comments,
identified by dock number and title, by
any of the following methods:
* Federal Rulemaking Portal: https://
www.regulations.gov. Follow the
instructions for submitting comments.
* Mail: Federal Docket Management
System Office, 1160 Defense Pentagon,
Washington, DC 20301–1160.
Instructions: All submissions received
must include the agency name and
docket number for this Federal Register
document. The general policy for
comments and other submissions from
members of the public is of make these
submissions available for public
viewing on the Internet at https://
www.regulations.gov as they are
received without change, including any
personal identifiers or contact
information.
FOR FURTHER INFORMATION CONTACT: Ms.
Theresa Lowery at (202) 231–1193.
E:\FR\FM\28MYN1.SGM
28MYN1
]]>Agencies
[Federal Register Volume 75, Number 103 (Friday, May 28, 2010)]
[Notices]
[Page 30003]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-12867]
[[Page 30003]]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Office of the Secretary
Federal Advisory Committee; Meeting of the Uniform Formulary
Beneficiary Advisory Panel
AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: Under the provisions of the Federal Advisory Committee Act of
1972 (title 5, United States Code (U.S.C.), Appendix, as amended) and
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended)
the Department of Defense announces that the Uniform Formulary
Beneficiary Advisory Panel (hereafter referred to as the Panel) will
meet on June 24, 2010, in Washington, DC. The meeting is open to the
public from 9 a.m. to 12 p.m., but seating is limited. A closed
Administrative Work Meeting will be held from 8 a.m. to 9 a.m.
DATES: The open meeting will be held on June 24, 2010, from 9 a.m.-12
p.m. Prior to the open meeting the Panel will conduct an Administrative
Work Meeting from 8 a.m. to 9 a.m. that is closed to the public.
ADDRESSES: The meeting will be held at the Naval Heritage Center
Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004.
FOR FURTHER INFORMATION CONTACT: Lieutenant Colonel Stacia Spridgen,
Designated Federal Officer, Uniform Formulary Beneficiary Advisory
Panel, 2450 Stanley Road, Suite 208, Ft. Sam Houston, TX 78234-6102,
Telephone: (210) 295-1271, Fax: (210) 295-2789, E-mail:
Baprequests@tma.osd.mil.
SUPPLEMENTARY INFORMATION:
Purpose of Meeting
The Panel will review and comment on recommendations made to the
Director, TRICARE Management Activity, by the Pharmacy and Therapeutics
Committee regarding the Uniform Formulary.
Meeting Agenda
Sign-In; Welcome and Opening Remarks; Public Citizen Comments;
Scheduled Therapeutic Class Reviews--Alpha Blockers for Benign
Prostatic Hyperplasia, Antilipidemics I, Designated Newly Approved
Drugs and Drugs recommended for non-formulary placement due to non-
compliance with Fiscal Year 2008 National Defense Authorization Act,
Section 703; Panel Discussions and Vote; and comments following each
therapeutic class review.
Meeting Accessibility
Pursuant to 5 U.S.C. 552b, as amended, and 41 CFR 102-3.140 through
102-3.165, and the availability of space this meeting is open to the
public. Seating is limited and will be provided only to the first 220
people signing in. All persons must sign in legibly.
Administrative Work Meeting
Prior to the public meeting the Panel will conduct an
Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss
administrative matters of the Panel. The Administrative Work Meeting
will be held at the Naval Heritage Center (see ADDRESSES). Pursuant to
41 CFR 102-3.160, the Administrative Work Meeting will be closed to the
public.
Written Statements
Pursuant to 41 CFR 102-3.105(j) and 102-3.140, the public or
interested organizations may submit written statements to the
membership of the Panel at any time or in response to the stated agenda
of a planned meeting. Written statements should be submitted to the
Panel's Designated Federal Officer (see FOR FURTHER INFORMATION
CONTACT). The Designated Federal Officer's contact information can be
obtained from the General Services Administration's Federal Advisory
Committee Act Database--https://www.fido.gov/facadatabase/public.asp.
Written statements that do not pertain to the scheduled meeting of
the Panel may be submitted at any time. However, if individual comments
pertain to a specific topic being discussed at a planned meeting, then
these statements must be submitted no later than 5 business days prior
to the meeting in question. The Designated Federal Officer will review
all submitted written statements and provide copies to all the
committee members.
Public Comments
In addition to written statements, the Panel will set aside 1 hour
for individuals or interested groups to address the Panel. To ensure
consideration of their comments, individuals and interested groups
should submit written statements as outlined in this notice; but if
they still want to address the Panel, then they will be afforded the
opportunity to register to address the Panel. The Panel's Designated
Federal Officer will have a ``Sign-Up Roster'' available at the Panel
meeting, for registration on a first-come, first-serve basis. Those
wishing to address the Panel will be given no more than 5 minutes to
present their comments, and at the end of the 1-hour time period no
further public comments will be accepted. Anyone who signs up to
address the Panel, but is unable to do so due to the time limitation,
may submit their comments in writing; however, they must understand
that their written comments may not be reviewed prior to the Panel's
deliberation. Accordingly, the Panel recommends that individuals and
interested groups consider submitting written statements instead of
addressing the Panel.
Dated: May 25, 2010.
Mitchell S. Bryman,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2010-12867 Filed 5-27-10; 8:45 am]
BILLING CODE 5001-06-P
